Study Title

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Study Details

Description:

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

Sponsor:

University Hospital, Grenoble

Contacts:

Pierre PITTET

ppittet@chu-grenoble.fr

0476766872

Marine FAURE

mfaure6@chu-grenoble.fr

0476766872

Government Study Link:

NCT06611891 - Click here to see study on

ClinicalTrials.gov

Drug Details

Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • SSTR+
Chelator: DOTA

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468